Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.3501 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
21 22 Next >
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. 
Via Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga
Analyst Expectations for bluebird bio's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
What 4 Analyst Ratings Have To Say About bluebird bio
Via Benzinga
Why Bluebird Bio (BLUE) Stock Is Getting Hammered
Bluebird Bio Inc (NASDAQ: BLUE) shares are trading lower by 10.0% to $6.55 Wednesday morning after the company announced a proposed public offering of common stock. 
Via Benzinga
1 Beaten-Down Stock That Has a Lot to Prove in 2023
This biotech looks like a high-risk, high-reward play. 
Via The Motley Fool
Skechers To Rally 40%? Here Are 10 Other Analyst Forecasts For Monday
Credit Suisse raised the price target for Exelon Corporation (NASDAQ: EXC) from $42 to $46. Credit Suisse analyst Nicholas Campanella maintained an Outperform rating. Exelon shares fell 0.1% to $42.32... 
Via Benzinga
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies. 
Via The Motley Fool
Tesla, Amazon, bluebird, Netflix, Discover Financial: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed over 1.2% lower on Wednesday, dragged by renewed concerns of a recession as U.S. retail sales declined by the most in 12 months, down 1.1% in December as against... 
Via Benzinga
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
PNC Financial, bluebird bio And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 300 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Is Zomedica (ZOM) Stock Up Today?
Zomedica (ZOM) stock is on the rise Wednesday after the company signed a strategic restructuring agreement with Qorvo Biotechnologies. 
Via InvestorPlace
Moderna (MRNA) Stock Pops on RSV Vaccine Trial Results
Moderna (MRNA) stock is on the move Wednesday alongside positive results from its latest Phase 3 mRNA-1345 vaccine trial. 
Via InvestorPlace
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
The Nasdaq looked poised for modest gains once again on Wednesday. 
Via The Motley Fool
Why is Bluebird Bio (BLUE) Stock Down 9% Today?
Bluebird Bio (BLUE) stock is slipping on Wednesday after the biotechnology company announced a proposed public offering. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning! 
Via InvestorPlace
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
2 Stocks That Could Double Your Money in 2023
These biotechs could crush the market, but there is more to the story. 
Via The Motley Fool
bluebird bio Sells Second Priority Review Voucher for $95 Million
From bluebird bio, Inc.
Via Business Wire
Newly Approved Drugs In US Command Over $200,000 On An Average
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003. 
Via Benzinga
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
From bluebird bio, Inc.
Via Business Wire
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
Both stocks have fallen brutally this year, but only one has a chance to recover soon. 
Via The Motley Fool
After Doubling in the Past 6 Months, Is This Stock a Buy?
This company has had a solid year, but there is still plenty of work ahead. 
Via The Motley Fool
FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol
Via Benzinga
BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment
In a counterintuitive move, traders are selling BLUE stock even as Bluebird Bio claims to be on track with its sickle cell disease treatment. 
Via InvestorPlace
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
From bluebird bio, Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.